Fiscal year 2026 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses IMVT in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named IMVT in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Eric Venker | $636,618 | $503,345 | $0 | $19,010,639 | $0 | $0 | $8,165 | $20,158,767 |
| Chief Executive Officer | ||||||||
| Peter Salzmann | 39,614 | 0 | 8,287,949 | 6,269,395 | 0 | 0 | 737,642 | 15,334,600 |
| Former Chief Executive Officer | ||||||||
| Tiago Girão | 455,493 | 224,396 | 3,631,717 | 3,293,508 | 0 | 0 | 11,323 | 7,616,437 |
| Chief Financial Officer | ||||||||
| Michael Geffner | 345,521 | 0 | 2,564,119 | 2,145,870 | 0 | 0 | 198,579 | 5,254,089 |
| Former Chief Medical Officer | ||||||||
| Eva Renee Barnett | 26,250 | 0 | 1,350,946 | 1,462,825 | 0 | 0 | 387,431 | 3,227,452 |
| Former Chief Financial Officer | ||||||||
| Melanie Gloria | 495,000 | 245,025 | 1,157,951 | 1,150,095 | 0 | 0 | 19,041 | 3,067,112 |
| Chief Operating Officer | ||||||||
| Jay Stout | 495,000 | 245,025 | 1,157,951 | 1,150,095 | 0 | 0 | 17,650 | 3,065,721 |
| Chief Technology Officer | ||||||||
| Christopher Van Tuyl | 495,000 | 245,025 | 771,962 | 766,726 | 0 | 0 | 17,064 | 2,295,777 |
| Chief Legal Officer and Corporate Secretary | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2026 total | FY2025 total | FY2024 total | Δ FY2025→2026 |
|---|---|---|---|---|
| Eric Venker | $20,158,767 | — | — | — |
| Peter Salzmann | 15,334,600 | 10,732,127 | 8,552,430 | +4,602,473 |
| Tiago Girão | 7,616,437 | — | — | — |
| Michael Geffner | 5,254,089 | 4,051,027 | — | +1,203,062 |
| Eva Renee Barnett | 3,227,452 | 3,970,734 | 3,338,969 | −743,282 |
| Melanie Gloria | 3,067,112 | 5,573,835 | — | −2,506,723 |
| Jay Stout | 3,065,721 | 3,979,353 | 4,039,880 | −913,632 |
| Christopher Van Tuyl | 2,295,777 | 5,948,339 | — | −3,652,562 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2026 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Tiago Girao | Chief Financial Officer | 2026-07-23 | D | 6,798 | $39 | $263,015 | Common | Form 4 ↗ |
| Jay Stout | Chief Technology Officer | 2026-07-23 | D | 2,857 | 39 | 110,537 | Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-07-24 | — | 1,500 | — | — | 1 insider, 1 accrual row | ||
| Atul Pande | Director | 2026-07-24 | D | 1,500 | 40 | 59,700 | Common | Form 4 ↗ |
| Atul Pande | Director | 2026-07-24 | A | 1,500 | 8 | 12,645 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Tiago Girao | Chief Financial Officer | 2026-07-23 | D | 6,798 | $39 | $263,015 | Common | Form 4 ↗ |
| Jay Stout | Chief Technology Officer | 2026-07-23 | D | 2,857 | 39 | 110,537 | Common | Form 4 ↗ |
| Atul Pande | Director | 2026-07-24 | D | 1,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Atul Pande | Director | 2026-07-24 | D | 1,500 | 40 | 59,700 | Common | Form 4 ↗ |
| Atul Pande | Director | 2026-07-24 | A | 1,500 | 8 | 12,645 | Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Melanie Gloria | RSU | 2025-04-01 | — | — | 76,181 | — | $1,157,951 |
| Michael Geffner | RSU | 2025-04-01 | — | — | 101,574 | — | 1,543,925 |
| Melanie Gloria | PSU | 2025-08-27 | — | 320,000 | 160,000 | — | 0 |
| Eva Renee Barnett | OPTION | 2025-04-20 | — | — | 478,563 | — | 121,046 |
| Eric Venker | OPTION | 2025-07-28 | — | — | 1,300,000 | — | 15,284,490 |
| Michael Geffner | PSU | 2025-08-27 | — | 320,000 | 160,000 | — | 0 |
| Eric Venker | RSU | 2025-07-28 | — | 1,475,000 | — | — | 1,493,438 |
| Peter Salzmann | RSU | 2025-04-20 | — | — | 280,362 | — | 4,247,485 |
| Eva Renee Barnett | RSU | 2025-04-01 | — | — | 88,878 | — | 1,350,946 |
| Michael Geffner | OPTION | 2025-11-21 | — | — | 192,001 | — | 612,406 |
| Tiago Girão | RSU | 2025-04-21 | — | — | 31,708 | — | 318,348 |
| Christopher Van Tuyl | OPTION | 2025-04-01 | — | — | 71,531 | — | 766,726 |
| Tiago Girão | RSU | 2025-05-01 | — | — | 208,388 | — | 3,313,369 |
| Jay Stout | RSU | 2025-04-01 | — | — | 76,181 | — | 1,157,951 |
| Eric Venker | OPTION | 2025-07-28 | — | — | 189,900 | — | 2,232,711 |
| Peter Salzmann | RSU | 2025-04-01 | — | — | 265,820 | — | 4,040,464 |
| Jay Stout | PSU | 2025-08-27 | — | 140,000 | 70,000 | — | 0 |
| Michael Geffner | RSU | 2025-11-21 | — | — | 44,765 | — | 1,020,194 |
| Eva Renee Barnett | OPTION | 2025-04-01 | — | — | 125,180 | — | 1,341,779 |
| Peter Salzmann | OPTION | 2025-04-20 | — | — | 392,559 | — | 2,256,330 |
| Jay Stout | OPTION | 2025-04-01 | — | — | 107,297 | — | 1,150,095 |
| Tiago Girão | OPTION | 2025-05-01 | — | — | 293,505 | — | 3,293,508 |
| Peter Salzmann | OPTION | 2025-04-01 | — | — | 374,395 | — | 4,013,065 |
| Michael Geffner | OPTION | 2025-04-01 | — | — | 143,063 | — | 1,533,464 |
| Melanie Gloria | OPTION | 2025-04-01 | — | — | 107,297 | — | 1,150,095 |
| Christopher Van Tuyl | RSU | 2025-04-01 | — | — | 50,787 | — | 771,962 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Melanie Gloria | $1,157,951 | $0 | $1,150,095 | 0.0% |
| Michael Geffner | 2,564,119 | 0 | 2,145,870 | 0.0% |
| Eva Renee Barnett | 1,350,946 | 0 | 1,462,825 | 0.0% |
| Eric Venker | 1,493,438 | 0 | 17,517,201 | 0.0% |
| Peter Salzmann | 8,287,949 | 0 | 6,269,395 | 0.0% |
| Tiago Girão | 3,631,717 | 0 | 3,293,508 | 0.0% |
| Christopher Van Tuyl | 771,962 | 0 | 766,726 | 0.0% |
| Jay Stout | 1,157,951 | 0 | 1,150,095 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Jay Stout | Option | 46,875 | 15.47 | — |
| Peter Salzmann | RSU | 56,408 | — | 1,401,175 |
| Jay Stout | RSU | 76,181 | — | 1,892,336 |
| Peter Salzmann | Option | 85,742 | 14.7 | — |
| Michael Geffner | Option | 35,794 | 30.78 | — |
| Michael Geffner | RSU | 25,000 | — | 621,000 |
| Christopher Van Tuyl | Option | 94,494 | 27.63 | — |
| Tiago Girão | RSU | 208,388 | — | 5,176,358 |
| Jay Stout | RSU | 31,250 | — | 776,250 |
| Peter Salzmann | Option | 70,687 | 4.99 | — |
| Melanie Gloria | RSU | 160,000 | — | 3,974,400 |
| Melanie Gloria | Option | 94,494 | 25.51 | — |
| Jay Stout | RSU | 30,926 | — | 768,202 |
| Christopher Van Tuyl | RSU | 50,787 | — | 1,261,549 |
| Michael Geffner | RSU | 101,574 | — | 2,523,098 |
| Melanie Gloria | RSU | 75,595 | — | 1,877,780 |
| Peter Salzmann | RSU | 76,198 | — | 1,892,758 |
| Christopher Van Tuyl | RSU | 75,595 | — | 1,877,780 |
| Melanie Gloria | RSU | 76,181 | — | 1,892,336 |
| Eric Venker | Option | 1,489,900 | 16.76 | — |
| Tiago Girão | Option | 293,505 | 15.9 | — |
| Jay Stout | Option | 107,297 | 15.2 | — |
| Peter Salzmann | RSU | 265,820 | — | 6,602,969 |
| Michael Geffner | Option | 143,063 | 15.2 | — |
| Michael Geffner | RSU | 160,000 | — | 3,974,400 |
| Peter Salzmann | Option | 374,395 | 15.2 | — |
| Melanie Gloria | Option | 107,297 | 15.2 | — |
| Peter Salzmann | RSU | 90,301 | — | 2,243,077 |
| Michael Geffner | Option | 37,500 | 18.06 | — |
| Peter Salzmann | Option | 104,515 | 30.78 | — |
| Michael Geffner | RSU | 30,926 | — | 768,202 |
| Jay Stout | Option | 35,794 | 30.78 | — |
| Jay Stout | RSU | 70,000 | — | 1,738,800 |
| Christopher Van Tuyl | Option | 71,531 | 15.2 | — |
| Tiago Girão | RSU | 31,708 | — | 878,312 |
We have a "pay-for-performance"-focused executive compensation philosophy. Consistent with this philosophy, our Compensation Committee believes that compensation should be designed to optimize company performance to increase stockholder value.
| CEO STI target (% of salary) | 72% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Compensia |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | false |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-09-02 | 180,772,822 | 8,437,839 | 91,903 | 95.54% | Passed |
| 2025 | 2025-08-27 | 158,995,232 | 1,244,731 | 4,437 | 99.22% | Passed |
| 2024 | 2024-08-12 | 128,494,310 | 3,249,170 | 4,325 | 97.53% | Passed |
| 2023 | 2023-08-21 | 115,397,185 | 825,452 | 8,173 | 99.28% | Passed |
| 2022 | 2022-08-17 | 87,519,754 | 14,824,750 | 14,186 | 85.5% | Passed |
| 2021 | 2021-09-09 | 62,227,944 | 20,375,831 | 146,325 | 75.33% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-09-02 | 95.54%a |
| 2025 | 2025-08-27 | 99.22%b |
| 2024 | 2024-08-12 | 97.53%c |
a. Voting standard not stated in the filing.
b. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total, and will have the same effect as "Against" votes.”.
c. Approved under the standard stated in the filing — “Abstentions will be counted towards the vote total, and will have the same effect as "Against" votes.”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 67 : 1 |
|---|---|
| CEO total compensation | $20,224,962 |
| Median employee compensation | $303,366 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Frank M. Torti, M.DIndependent · Board Chair · Compensation | $92,500 | $3,030,348 | $971,380 | — | $0 | $4,094,228 |
| Jacob BauerIndependent · Audit (Chair) · Nominating/Governance | 71,497 | 397,754 | 392,824 | — | 0 | 862,075 |
| Robert SusmanIndependent · Audit · Compensation | 64,348 | 397,754 | 392,824 | — | 0 | 854,926 |
| George MigauskyIndependent · Not standing for re-election · Departed during FY | 3,306 | 491,307 | 175,042 | — | 0 | 669,655 |
| Andrew FromkinIndependent · Compensation (Chair) · Nominating/Governance | 72,734 | 246,058 | 78,559 | — | 0 | 397,351 |
| Douglas HughesIndependent · Audit · Compensation | 67,500 | 246,058 | 78,559 | — | 0 | 392,117 |
| Atul Pande, M.DIndependent · Nominating/Governance (Chair) | 60,233 | 246,058 | 78,559 | — | 0 | 384,850 |
| Eric Venker, M.D., Pharm.DEmployee director | 2,597 | 0 | 0 | — | 0 | 2,597 |
| Peter Salzmann, M.DEmployee director · Not standing for re-election · Departed during FY | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $425,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 17,500 / 10,000 |
| Stock ownership guideline | — |
| Component | FY2026 |
|---|---|
| Cash retainers and fees | $434,715 |
| Equity awards (grant-date value) | $5,055,337 |
| All other compensation | $0 |
| Total cost of the board | $5,490,052 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Immunovant names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Immunovant.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Arcellx | 2024 | Rami Elghandour | $653,288 | $9,342,069 | $10,850,151 | $0 | $21,402,668 |
| 2 | Immunovant | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 3 | Madrigal Pharmaceuticals | 2025 | Bill Sibold | 918,531 | 12,297,850 | 4,537,146 | 1,438,814 | 19,206,341 |
| 4 | SpringWorks Therapeutics | 2024 | Saqib Islam | 760,000 | 7,899,760 | 6,689,100 | 798,000 | 16,153,317 |
| 5 | BridgeBio Pharma | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 6 | Biohaven | 2025 | Vlad Coric | 920,400 | 2,202,480 | 9,900,043 | 0 | 13,500,438 |
| 7 | Cytokinetics | 2025 | Robert Blum | 853,069 | 5,150,019 | 5,095,918 | 772,715 | 11,881,456 |
| 8 | Nuvalent | 2025 | James Porter | 652,100 | 4,392,563 | 5,857,906 | 469,512 | 11,393,602 |
| 9 | Xenon Pharmaceuticals | 2025 | Ian Mortimer | 786,000 | 1,774,000 | 6,065,255 | 550,200 | 9,221,712 |
| 10 | Arrowhead Pharmaceuticals | 2025 | Christopher Anzalone | 981,046 | 6,810,292 | 0 | 1,236,000 | 9,029,861 |
| 11 | Kymera Therapeutics | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 12 | CRISPR Therapeutics AG | 2025 | Samarth Kulkarni | 768,622 | 3,474,900 | 2,768,862 | 659,093 | 7,678,477 |
| 13 | Viridian Therapeutics | 2025 | Stephen Mahoney | 700,000 | 1,058,098 | 4,381,713 | 630,000 | 6,776,249 |
| 14 | Xencor | 2025 | Bassil Dahiyat | 742,800 | 1,552,892 | 2,727,018 | 490,248 | 5,521,205 |
| 15 | Celldex Therapeutics | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 16 | Denali Therapeutics | 2025 | Ryan Watts | 718,000 | 1,151,867 | 2,180,003 | 0 | 4,751,515 |
| — | Apogee Therapeutics | — | — | — | — | — | — | not in coverage universe |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Immunovant | 110% | not disclosed | No | Compensia |
| Apogee Therapeutics | not disclosed | not disclosed | not disclosed | not disclosed |
| Arcellx | 140% | not disclosed | No | Meridian Compensation Partners, LLC |
| Arrowhead Pharmaceuticals | 125% | PSU 70 · RSU 30 | not disclosed | Compensia |
| Biohaven | 67% | not disclosed | not disclosed | Aon Human Capital Solutions |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Celldex Therapeutics | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| CRISPR Therapeutics AG | 122.5% | not disclosed | not disclosed | Alpine Rewards, LLC |
| Cytokinetics | 120% | RSU 50 · Options 50 | not disclosed | Aon Human Capital Solutions |
| Denali Therapeutics | 145% | not disclosed | not disclosed | Alpine Rewards |
| Kymera Therapeutics | 125% | not disclosed | No | Alpine Rewards |
| Madrigal Pharmaceuticals | 195% | PSU 33 · RSU 33 · Options 33 | Yes — Relative TSR vs Nasdaq Biotechnology Index | Compensia |
| Nuvalent | 120% | not disclosed | No | Alpine Rewards |
| SpringWorks Therapeutics | 140% | not disclosed | Yes — Relative Total Shareholder Return (TSR) | Aon plc (Human Capital Solutions practice) |
| Viridian Therapeutics | 150% | Options 75 · RSU 25 | not disclosed | Compensia |
| Xencor | 110% | Options 60 · RSU 40 | not disclosed | Aon |
| Xenon Pharmaceuticals | 100% | not disclosed | No | Aon |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Eric Venker | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “FY2026 Summary Compensation Table”. As printed: 20,158,767. Filing ↗machine: span 465716–465726 |
| 2 | Section 01, Peter Salzmann | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “FY2026 Summary Compensation Table”. As printed: 15,334,600. Filing ↗machine: r16 · c42 · span 491355–491365 |
| 3 | Section 01, Tiago Girão | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “FY2026 Summary Compensation Table”. As printed: 7,616,437. Filing ↗machine: r4 · c42 · span 468992–469001 |
| 4 | Section 01, Michael Geffner | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “FY2026 Summary Compensation Table”. As printed: 5,254,089. Filing ↗machine: span 508374–508383 |
| 5 | Section 01, Eva Renee Barnett | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “FY2026 Summary Compensation Table”. As printed: 3,227,452. Filing ↗machine: r20 · c42 · span 500249–500258 |
| 6 | Section 01, Melanie Gloria | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “FY2026 Summary Compensation Table”. As printed: 3,067,112. Filing ↗machine: span 472542–472551 |
| 7 | Section 01, Jay Stout | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “FY2026 Summary Compensation Table”. As printed: 3,065,721. Filing ↗machine: span 478087–478096 |
| 8 | Section 01, Christopher Van Tuyl | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “FY2026 Summary Compensation Table”. As printed: 2,295,777. Filing ↗machine: t24 · r13 · c14 · span 485528–485537 |
| 9 | Section 03, Melanie Gloria RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r13 · c21 · span 554233–554242 |
| 10 | Section 03, Michael Geffner RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r35 · c21 · span 610164–610173 |
| 11 | Section 03, Melanie Gloria PSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r15 · c5 · span 558565–558572 |
| 12 | Section 03, Eva Renee Barnett OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r33 · c21 · span 605709–605716 |
| 13 | Section 03, Eric Venker OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r4 · c23 · span 531527–531537 |
| 14 | Section 03, Michael Geffner PSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t14 · r14 · c1 · span 276494–276495 |
| 15 | Section 03, Eric Venker RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t38 · r4 · c8 · span 965833–965842 |
| 16 | Section 03, Peter Salzmann RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r28 · c21 · span 591254–591263 |
| 17 | Section 03, Eva Renee Barnett RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r31 · c21 · span 599234–599243 |
| 18 | Section 03, Michael Geffner OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r39 · c21 · span 623674–623681 |
| 19 | Section 03, Tiago Girão RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r8 · c21 · span 542660–542667 |
| 20 | Section 03, Christopher Van Tuyl OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r24 · c20 · span 580590–580597 |
| 21 | Section 03, Tiago Girão RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r9 · c20 · span 546131–546140 |
| 22 | Section 03, Jay Stout RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r18 · c21 · span 565801–565810 |
| 23 | Section 03, Eric Venker OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r5 · c21 · span 534813–534822 |
| 24 | Section 03, Peter Salzmann RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r26 · c21 · span 584783–584792 |
| 25 | Section 03, Jay Stout PSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r20 · c5 · span 570133–570139 |
| 26 | Section 03, Michael Geffner RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r38 · c21 · span 620151–620160 |
| 27 | Section 03, Eva Renee Barnett OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r32 · c20 · span 602448–602457 |
| 28 | Section 03, Peter Salzmann OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r29 · c21 · span 594776–594785 |
| 29 | Section 03, Jay Stout OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r19 · c20 · span 569015–569024 |
| 30 | Section 03, Tiago Girão OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r10 · c20 · span 549345–549354 |
| 31 | Section 03, Peter Salzmann OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r27 · c20 · span 587997–588006 |
| 32 | Section 03, Michael Geffner OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r36 · c20 · span 613378–613387 |
| 33 | Section 03, Melanie Gloria OPTION | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r14 · c20 · span 557447–557456 |
| 34 | Section 03, Christopher Van Tuyl RSU | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t26 · r23 · c21 · span 577379–577386 |
| 35 | Section 07, pay ratio | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “CEO Pay Ratio”. As printed: 67 : 1. Filing ↗machine: span 869471–869473 |
| 36 | Section 08, Frank M. Torti, M.D | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Director Compensation”. As printed: 4,094,228. Filing ↗ |
| 37 | Section 08, Jacob Bauer | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Director Compensation”. As printed: 862,075. Filing ↗machine: t42 · r3 · c11 · span 1018955–1018962 |
| 38 | Section 08, Robert Susman | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Director Compensation”. As printed: 854,926. Filing ↗machine: t42 · r7 · c11 · span 1027368–1027375 |
| 39 | Section 08, George Migausky | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Director Compensation”. As printed: 669,655. Filing ↗machine: t42 · r9 · c11 · span 1032287–1032294 |
| 40 | Section 08, Andrew Fromkin | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Director Compensation”. As printed: 397,351. Filing ↗machine: t42 · r4 · c11 · span 1021109–1021116 |
| 41 | Section 08, Douglas Hughes | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Director Compensation”. As printed: 392,117. Filing ↗machine: t42 · r5 · c11 · span 1023263–1023270 |
| 42 | Section 08, Atul Pande, M.D | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Director Compensation”. As printed: 384,850. Filing ↗ |
| 43 | Section 08, Eric Venker, M.D., Pharm.D | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Director Compensation”. As printed: 2,597. Filing ↗ |
| 44 | Section 08, Peter Salzmann, M.D | DEF 14A | 2026-07-22 | 0001764013-26-000092 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 45 | Section 02, Tiago Girao 2026-07-23 | Form 4 | 2026-07-24 | 0001618670-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Jay Stout 2026-07-23 | Form 4 | 2026-07-24 | 0001702969-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Atul Pande 2026-07-24 | Form 4 | 2026-07-24 | 0001643071-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Atul Pande 2026-07-24 | Form 4 | 2026-07-24 | 0001643071-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Atul Pande 2026-07-24 | Form 4 | 2026-07-24 | 0001643071-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 06, 2026 vote | Form 8-K | 2026-09-03 | 0001764013-26-000106 | Item 5.07 · say-on-pay result. As reported: 95.54% (votes for as printed: 180,772,822). Filing ↗ |
| 51 | Section 06, 2025 vote | Form 8-K | 2025-08-28 | 0001764013-25-000132 | Item 5.07 · say-on-pay result. As reported: 99.22% (votes for as printed: 158,995,232). Filing ↗ |
| 52 | Section 06, 2024 vote | Form 8-K | 2024-08-13 | 0001764013-24-000150 | Item 5.07 · say-on-pay result. As reported: 97.53% (votes for as printed: 128,494,310). Filing ↗ |
| 53 | Section 01 trend, Δ column (computed) | Computed | — | computed | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 54 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 55 | Section 09b board cost (computed) | Computed | — | computed | Cash 434,715 + equity 5,055,337 + all other 0 = 5,490,052, summed across the director compensation table rows.machine: formula: Σ = 5,490,052 |
| 56 | Arcellx, Section 10b CEO total | DEF 14A | 2025-04-17 | 0001193125-25-084363 | CEO total compensation as printed in Arcellx's own proxy. As printed: 21,402,668. Filing ↗machine: r2 · c31 · span 471887–471897 |
| 57 | Immunovant (subject), Section 10b CEO total | DEF 14A | 2026-07-22 | 0001764013-26-000092 | CEO total compensation as printed in Immunovant's own proxy. As printed: 20,158,767. Filing ↗machine: span 465716–465726 |
| 58 | Madrigal Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001308179-26-000352 | CEO total compensation as printed in Madrigal Pharmaceuticals's own proxy. As printed: 19,206,341. Filing ↗machine: r2 · c24 · span 791942–791952 |
| 59 | SpringWorks Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-04 | 0001104659-25-032187 | CEO total compensation as printed in SpringWorks Therapeutics's own proxy. As printed: 16,153,317. Filing ↗machine: t23 · r1 · c44 · span 623184–623194 |
| 60 | BridgeBio Pharma, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 61 | Biohaven, Section 10b CEO total | DEF 14A | 2026-03-13 | 0001935979-26-000028 | CEO total compensation as printed in Biohaven's own proxy. As printed: 13,500,438. Filing ↗machine: t25 · r3 · c7 · span 423429–423439 |
| 62 | Cytokinetics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001140361-26-015364 | CEO total compensation as printed in Cytokinetics's own proxy. As printed: 11,881,456. Filing ↗machine: r2 · c25 · span 777093–777103 |
| 63 | Nuvalent, Section 10b CEO total | DEF 14A | 2026-04-28 | 0001861560-26-000013 | CEO total compensation as printed in Nuvalent's own proxy. As printed: 11,393,602. Filing ↗machine: r2 · c14 · span 689237–689247 |
| 64 | Xenon Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-22 | 0001193125-26-170320 | CEO total compensation as printed in Xenon Pharmaceuticals's own proxy. As printed: 9,221,712. Filing ↗machine: r2 · c28 · span 968086–968095 |
| 65 | Arrowhead Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-01-27 | 0000879407-26-000019 | CEO total compensation as printed in Arrowhead Pharmaceuticals's own proxy. As printed: 9,029,861. Filing ↗machine: span 692475–692484 |
| 66 | Kymera Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001193125-26-191495 | CEO total compensation as printed in Kymera Therapeutics's own proxy. As printed: 8,545,609. Filing ↗machine: r2 · c14 · span 676137–676146 |
| 67 | CRISPR Therapeutics AG, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001193125-26-165158 | CEO total compensation as printed in CRISPR Therapeutics AG's own proxy. As printed: 7,678,477. Filing ↗machine: t21 · r2 · c26 · span 821649–821658 |
| 68 | Viridian Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001193125-26-160344 | CEO total compensation as printed in Viridian Therapeutics's own proxy. As printed: 6,776,249. Filing ↗machine: r2 · c35 · span 371769–371778 |
| 69 | Xencor, Section 10b CEO total | DEF 14A | 2026-04-27 | 0001326732-26-000031 | CEO total compensation as printed in Xencor's own proxy. As printed: 5,521,205. Filing ↗machine: t32 · r3 · c19 · span 631325–631334 |
| 70 | Celldex Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001104659-26-050884 | CEO total compensation as printed in Celldex Therapeutics's own proxy. As printed: 5,366,709. Filing ↗machine: r1 · c54 · span 1024857–1024866 |
| 71 | Denali Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-21 | 0001714899-26-000054 | CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614 |
| 72 | Section 10a, Arcellx reciprocity | DEF 14A | — | 0001193125-25-084363 | Arcellx's most recent proxy was read; its disclosed peer group does not include Immunovant. Filing ↗ |
| 73 | Section 10a, BridgeBio Pharma reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma's most recent proxy was read; its disclosed peer group does not include Immunovant. Filing ↗ |
| 74 | Section 10a, Xencor reciprocity | DEF 14A | — | 0001326732-26-000031 | Xencor's most recent proxy was read; its disclosed peer group does not include Immunovant. Filing ↗ |
| 75 | Section 10a, Nuvalent reciprocity | DEF 14A | — | 0001861560-26-000013 | Nuvalent names Immunovant in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 76 | Section 10a, Kymera Therapeutics reciprocity | DEF 14A | — | 0001193125-26-191495 | Kymera Therapeutics names Immunovant in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 77 | Section 10a, Arrowhead Pharmaceuticals reciprocity | DEF 14A | — | 0000879407-26-000019 | Arrowhead Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Immunovant. Filing ↗ |
| 78 | Section 10a, CRISPR Therapeutics AG reciprocity | DEF 14A | — | 0001193125-26-165158 | CRISPR Therapeutics AG's most recent proxy was read; its disclosed peer group does not include Immunovant. Filing ↗ |
| 79 | Section 10a, Xenon Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-170320 | Xenon Pharmaceuticals names Immunovant in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 80 | Section 10a, Madrigal Pharmaceuticals reciprocity | DEF 14A | — | 0001308179-26-000352 | Madrigal Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Immunovant. Filing ↗ |
| 81 | Section 10a, Viridian Therapeutics reciprocity | DEF 14A | — | 0001193125-26-160344 | Viridian Therapeutics names Immunovant in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 82 | Section 10a, Celldex Therapeutics reciprocity | DEF 14A | — | 0001104659-26-050884 | Celldex Therapeutics names Immunovant in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 83 | Section 10a, Denali Therapeutics reciprocity | DEF 14A | — | 0001714899-26-000054 | Denali Therapeutics's most recent proxy was read; its disclosed peer group does not include Immunovant. Filing ↗ |
| 84 | Section 10a, Biohaven reciprocity | DEF 14A | — | 0001935979-26-000028 | Biohaven names Immunovant in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 85 | Section 10a, Cytokinetics reciprocity | DEF 14A | — | 0001140361-26-015364 | Cytokinetics names Immunovant in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 86 | Section 10a, SpringWorks Therapeutics reciprocity | DEF 14A | — | 0001104659-25-032187 | SpringWorks Therapeutics names Immunovant in its own disclosed peer group (read from its most recent proxy). Filing ↗ |